Theorem Clinical Research and Excel Life Sciences have formed a strategic relationship.
Theorem Clinical Researchand Excel Life Sciences (ELS) have formed a strategic relationship to bolster Theorem’s clinical development offerings in India, including local site management expertise. ELS has long-standing relationships with more than 1,000 hospitals and research centers across 25 cities throughout India, covering a broad range of therapeutic disciplines.
“ELS complements our own strategic offerings in the region and around the globe and extends our clinical trial capabilities,” said Marc Hoffman, M.D., Theorem senior vice president and general manager of biopharmaceutical development. “Collaborating together we can offer sponsor companies access to a wealth of high-quality research centers in India, a well-established research team with a strong understanding of ICH-GCP and, most importantly, the local knowledge for successful conduct of studies in country. There are obvious benefits for all: for sponsors, more robust patient recruitment and retention and, for patients, access to cutting-edge therapies and research programs.”
ELS has developed one of the largest networks of investigators and investigative sites within India.
“Site management services from Excel Life Sciences help take the burden off investigators so they can focus on patient care and ensure that the study is conducted to the highest standards for quality, ethics and performance,” said Vijai Kumar, M.D., president and chief medical officer of ELS. “This support ensures collection of high-quality study data necessary for the U.S. Food and Drug Administration, the European Medicines Agency and other global regulatory and product approval agencies. Operationally, our site management focus has translated into India patient enrollment and retention numbers that are significantly higher than comparative global performance for the same study.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.